ArticleKidney diseases (Basel, Switzerland)
Association between Antihistamine Use and Clinical Outcomes in Patients on Maintenance Hemodialysis.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: H1 antihistamines are frequently used to treat pruritus in patients on dialysis, but their safety remains unclear. This study aimed to evaluate the effects of H1 antihistamine use on outcomes in patients undergoing maintenance hemodialysis (HD). Methods: This retrospective cohort study included adult patients undergoing HD identified through national HD quality assessment programs. Patients were grouped by H1 antihistamine use over 6 months: no prescription, short (<60 days), and long (≥60 days) groups. Outcomes included all-cause mortality, cardiovascular events (CVEs), atrial fibrillation (AF), dementia, and Parkinson's disease. Cox regression was used to estimate hazard ratios (HRs). Results: Among 71,540 patients, 22.9%, 34.4%, and 42.6% were classified into the no prescription, short, and long groups, respectively. H1 antihistamine use was associated with higher risks of adverse outcomes, with significantly greater HRs in the long group than in the short group. Compared to the no prescription group, the adjusted HRs (95% confidence interval) in the long group were 1.12 (1.08-1.15) for all-cause mortality, 1.17 (1.12-1.23) for CVE, 1.06 (1.01-1.12) for AF, 1.31 (1.23-1.41) for dementia, and 1.47 (1.30-1.67) for Parkinson's disease. These associations remained consistent irrespective of insomnia status, except for AF, where increased risk was only observed in patients without insomnia. First-generation antihistamines were linked to greater risks of all-cause mortality, CVE, and dementia, but not for AF and Parkinson's disease, compared to second-generation agents. Conclusions: H1 antihistamine use, particularly long-term use and first-generation agents, was associated with increased risks of adverse outcomes in patients undergoing HD. These findings suggest that antihistamine use may represent a potential risk marker in this population; however, the observed associations may reflect the presence or severity of pruritus rather than that of a direct causal effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.